Duke Street Bio announces first patient dosed in Phase I trial with DSB2455, a next deneration PARP1 selective inhibitor for the treatment of solid tumours
December 3, 2024

December 3, 2024
November 14, 2024
November 8, 2024
September 26, 2024
September 24, 2024
September 18, 2024
August 12, 2024
July 23, 2024
July 22, 2024
June 16, 2026
New ultra-high-throughput kit enables discovery teams to generate transcriptome-wide compound-response data directly from 1536-well plates Alithea Gen...
June 16, 2026
Seasoned Biopharmaceutical Leader and Board Director Steps Up to Lead the Company’s Next Phase of Growth in Customized Interleukin Therapies ARScience...
June 8, 2026
Alithea Genomics, a pioneering biotech company specializing in scalable RNA sequencing solutions, today announced a new agreement with Revvity Inc. to...

Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225